Squamous Cell Carcinoma Antigen, Tumor-Associated Trypsin Inhibitor, and Carcinoembryonic Antigen for Monitoring Cervical Cancer

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

“…While five patients showed some decrease in SCC serum levels all others with detectable tumor marker had stable or steadily increasing levels. Estimation of SCC in cervical cancer represents a useful tool for monitoring the efficacy of treatment in advanced stages or relapse and correlates closely with stage and tumor burden (Pectasides et al 1994;Micke et al 2000). In relapsing or untreated patients a steady increase is regularly observed (Meier et al 1997).…”

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

“…Serum SCC concentration has a sensitivity between 56% and 86% and specificity between 83% and 100% for detecting recurrent squamous cell cervical cancer (386,388,392,396,398,401,407,409,412 ). With the use of SCC, a lead time of up to 14 months for detecting recurrent disease has been reported, with a mean or median between 2 and 6 months (386, 388, 396 -398, 400, 401, 403, 405, 407 ).…”

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

“…Serial SCC measurements reflect both the tumour response to radiotherapy and/or chemotherapy and the clinical outcome of patients [14,18,22,26,27,29,31,37,47]. In a German study 60% of 72 patients with squamous cell cervical cancer undergoing radiotherapy had pre-therapeutic serum SCC > 2.5 ng/ml, whereas antigen levels after the end of radiotherapy were above this cut-off in 2% of the patients in complete response and in 13% of those in partial response [26].…”

“…Increasing serum SCC can precede the clinical diagnosis of relapse in 46-92% of the cases, with a mean lead time ranging from 2 to 7.8 months [18,21,22,25,26,[47][48][49][50][51] ( Table 3). Dodd et al [48] found elevated antigen levels before the clinical evidence of recurrence in 12 (50%) and at the time of recurrence in 6 (25%) of 24 patients with fatal squamous cell cervical cancer.…”